Ubiquilin 2 Is Not Associated with Tau Pathology

A. Nölle, E.S. van Haastert, R. Zwart, J.J.M. Hoozemans, W. Scheper

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Accumulation of aberrant proteins in inclusion bodies is a hallmark of many neurodegenerative diseases. Impairment of proteolytic systems is a common event in these protein misfolding diseases. Recently, mutations in the UBQLN 2 gene encoding ubiquilin 2 have been identified in X-linked amyotrophic lateral sclerosis (ALS). Furthermore, ubiquilin 2 is associated with inclusions in familial and sporadic ALS/dementia, synucleinopathies and polyglutamine diseases. Ubiquilin 2 exerts a regulatory role in proteostasis and thus it has been suggested that ubiquilin 2 pathology may be a common event in neurodegenerative diseases. Tauopathies, a heterogenous group of neurodegenerative diseases accompanied with dementia, are characterized by inclusions of the microtubule-binding protein tau. In the present study, we investigate whether ubiquilin 2 is connected with tau pathology in Alzheimer's disease (AD), supranuclear palsy (PSP) and Pick's disease (PiD) and familial cases with frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). We show that ubiquilin 2 positive inclusions are absent in these tauopathies. Furthermore, we find decreased ubiquilin 2 protein levels in AD patients, but our results do not indicate a correlation with tau pathology. Our data show no evidence for involvement of ubiquilin 2 and indicate that other mechanisms underly the proteostatic disturbances in tauopathies. © 2013 Nölle et al.
Original languageEnglish
Article numbere76598
JournalPLoS ONE
Volume8
Issue number9
DOIs
Publication statusPublished - 26 Sep 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Ubiquilin 2 Is Not Associated with Tau Pathology'. Together they form a unique fingerprint.

Cite this